Logo

American Heart Association

  133
  0


Final ID: MDP874

Association of Sociodemographic Characteristics on Costs of Care in Patients with Obstructive Hypertrophic Cardiomyopathy

Abstract Body (Do not enter title and authors here): Introduction: No evidence exists on the impact of sociodemographic characteristics on costs of care for obstructive hypertrophic cardiomyopathy (oHCM). Therefore, we evaluated 5-year cumulative costs by age, sex, and race/ethnicity.
Methods: Retrospective cohort study of adults diagnosed with oHCM (January 2013 to December 2021) using Optum claims and electronic medical record data. Patients with ≥2 claims for HCM (ICD-9 and-10) at least 30 days apart (index date = earliest oHCM claim) with ≥1 additional oHCM claim or septal reduction therapy, 6-months pre-index and 5-year post-index continuous enrollment were included. HCM-related cumulative costs (2022 CPI adjusted) were reported for medical (ambulatory [AB]: office [OV] visits, outpatient [OP] visits); emergency room [ER] visits; inpatient admissions (IP); and pharmacy (Rx).
Results: Among 5,129 patients with oHCM, 52% were female (mean age 63.9 ± 14.3 years; 77.6% non-Hispanic White; 40% Medicare). Compared to females (Table), male patients had greater costs including total ($71,581 vs $63,710, p= 0.014), medical ($70,395 vs $62,455, p= 0.013), ambulatory ($16,024 vs $10,776, p<0.001), OV ($1,906 vs $1,573, p<0.001), and OP ($14,118 vs $9,202, p<0.001). Compared with White patients, Black patients had significantly greater IP costs ($54,572 vs $42,686, p= 0.01), Hispanic patients had greater ER costs ($1,724 vs $791, p<0.001), and Asian patients had greater OV costs ($2,094 vs $1,800, p<0.001). Patients aged 18-39 years had greater costs across all categories (p<0.001; IP=NS), except Rx. Patients aged 40-54 years had the highest Rx costs ($1,557, p<0.001), followed by 18-39, 55-64, 65-74, 75+ years ($1,528; $1,329; $1,197; $867), respectively.
Conclusions: For oHCM patients, being male and age 18-39 years was associated with increased HCM-related healthcare costs. Differences in cost across race/ethnicity exist, including greater IP and ER costs for Black and Hispanic patients, respectively. Future research is required to understand the source of these differences among oHCM patients.
  • Reza, Nosheen  ( Perelman School of Medicine at the University of Pennsylvania , Philadelphia , Pennsylvania , United States )
  • Butzner, Michael  ( Cytokinetics, Inc. , South San Francisco , California , United States )
  • Batra, Kirti  ( Optum , Eden Prarie , Minnesota , United States )
  • Amos, Qiana  ( Optum , Eden Prarie , Minnesota , United States )
  • Buikema, Ami  ( Optum , Eden Prarie , Minnesota , United States )
  • Anderson, Amy  ( Optum , Eden Prarie , Minnesota , United States )
  • Shreay, Sanatan  ( Cytokinetics, Inc. , South San Francisco , California , United States )
  • Owens, Anjali  ( Perelman School of Medicine at the University of Pennsylvania , Philadelphia , Pennsylvania , United States )
  • Author Disclosures:
    Nosheen Reza: DO have relevant financial relationships ; Advisor:American Regent:Past (completed) ; Advisor:Bristol Myers Squibb:Past (completed) ; Research Funding (PI or named investigator):Bristol Myers Squibb:Active (exists now) ; Advisor:Roche Diagnostics:Past (completed) ; Speaker:Zoll:Past (completed) | Michael Butzner: DO have relevant financial relationships ; Employee:Cytokinetics, Inc.:Active (exists now) ; Individual Stocks/Stock Options:Cytokinetics, Inc.:Active (exists now) | Kirti Batra: DO NOT have relevant financial relationships | Qiana Amos: No Answer | Ami Buikema: DO have relevant financial relationships ; Employee:Optum:Active (exists now) ; Other (please indicate in the box next to the company name):Cytokinetics - Contracted with Optum to conduct the research:Active (exists now) | Amy Anderson: No Answer | Sanatan Shreay: No Answer | Anjali Owens: DO have relevant financial relationships ; Consultant:BMS:Active (exists now) ; Consultant:corvista:Active (exists now) ; Consultant:stealth:Active (exists now) ; Consultant:Edgewise:Active (exists now) ; Consultant:Alexion:Active (exists now) ; Consultant:Lexicon:Active (exists now) ; Consultant:Lexeo:Active (exists now) ; Consultant:Tenaya:Active (exists now) ; Consultant:biomarin:Active (exists now) ; Consultant:Cytokinetics:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Socioeconomic Insights and Innovations in Heart Failure

Sunday, 11/17/2024 , 09:30AM - 10:55AM

Moderated Digital Poster Session

More abstracts on this topic:
APOL1 Risk Variants and Risk of Incident Atrial Fibrillation in Systolic Blood Pressure Intervention Trial (SPRINT)

Ahmad Muhammad, Kazibwe Richard, Mostafa Mohamed, Naeem Rimsha, Singh Sanjay, Bansal Nisha, Soliman Elsayed

Commercial Pricing of Percutaneous Coronary Intervention in The United States

Wei Chen, Paranjpe Ishan, Sharma Pranav, Song Nancy, Lan Roy, Sahu Maitreyi, Dieleman Joseph, Schulman Kevin, Sandhu Alexander

More abstracts from these authors:
You have to be authorized to contact abstract author. Please, Login
Not Available